# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The data reinforce previous findings on the safety and effectiveness of LUPKYNIS (voclosporin), a second generation calcineurin...
Outlines Concerns Regarding the Company's Current Strategy and Board Composition and Offers Superior Paths to Improving Per...
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate ...
The updated label no longer includes language indicating that the safety and efficacy of LUPKYNIS has not been established beyo...
HC Wainwright & Co. analyst Ed Arce reiterates Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy and maintains $13 price ...
Cantor Fitzgerald analyst Olivia Brayer maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Overweight and lowers the pri...